Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
LetterCorrespondence

Rare Side Effects of Subcutaneous Methotrexate Therapy

SHAILENDRA KAPOOR
The Journal of Rheumatology February 2013, 40 (2) 205; DOI: https://doi.org/10.3899/jrheum.121099
SHAILENDRA KAPOOR
Mechanicsville, Virginia, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: shailendrakapoor@yahoo.com
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

I read with great interest the recent report by Hassanzadeh, et al1. Subcutaneous methotrexate (MTX) may rarely be associated with a number of unique side effects.

Pulmonary complications such as pneumonitis have been reported following the use of subcutaneous MTX2. Similarly, the uses of subcutaneous MTX may be associated with the development of tumors such as pylomatrixomas3. Cutaneous B cell lymphomas may develop at the subcutaneous injection site. For instance, Giard, et al have reported the development of Epstein-Barr virus-associated B cell lymphomas at the subcutaneous injection site4.

Semicircular atrophy is another rare dermatological complication. It is especially seen in children who are administered subcutaneous MTX5. It is more common when the MTX is administered in the anterior thigh region. Rarely, the neurological system may also be involved. Neurological symptoms may include weakness and dysmetria2. Dysarthria has also been reported following subcutaneous MTX administration. Neurological findings such as hyporeflexia and magnetic gait may be seen.

The above examples highlight the rare complications of subcutaneous MTX and the need to monitor these patients for the development of these side effects.

REFERENCES

  1. 1.↵
    1. Hassanzadeh R,
    2. Mangan C,
    3. France J,
    4. Bawa S
    . Subcutaneous methotrexate to cut costs? [letter]. J Rheumatol 2012;39:1764–5.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Sommer WH,
    2. Ganiere V,
    3. Gachoud D,
    4. Keta A,
    5. Abou-Hajar A,
    6. Dudler J,
    7. et al.
    Neurological and pulmonary adverse effects of subcutaneous methotrexate therapy. Scand J Rheumatol 2008;37:306–9.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Afonso Perez E,
    2. Garcia Porrua C,
    3. Castineiras Mato IM,
    4. Bal Nieves F
    . Development of pylomatrixoma after the subcutaneous injection of methotrexate for the treatment of juvenile idiopathic arthritis. Reumatol Clin 2012;8:380–1.
    OpenUrlPubMed
  4. 4.↵
    1. Giard C,
    2. Avenel-Audran M,
    3. Croue A,
    4. Verret JL,
    5. Martin L
    . Primary cutaneous Epstein-Barr virus-associated B-cell lymphoma arising at the site of subcutaneous injections of methotrexate. J Clin Oncol 2010;28:e717–8.
    OpenUrlFREE Full Text
  5. 5.↵
    1. Haas N,
    2. Henz BM,
    3. Bunikowski R,
    4. Keitzer R
    . Semicircular lipoatrophy in a child with systemic lupus erythematosus after subcutaneous injections with methotrexate. Pediatr Dermatol 2002;19:432–5.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 40, Issue 2
1 Feb 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Rare Side Effects of Subcutaneous Methotrexate Therapy
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rare Side Effects of Subcutaneous Methotrexate Therapy
SHAILENDRA KAPOOR
The Journal of Rheumatology Feb 2013, 40 (2) 205; DOI: 10.3899/jrheum.121099

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Rare Side Effects of Subcutaneous Methotrexate Therapy
SHAILENDRA KAPOOR
The Journal of Rheumatology Feb 2013, 40 (2) 205; DOI: 10.3899/jrheum.121099
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • REFERENCES
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Frequency of Allopurinol Dose Reduction in Hospitalized Patients With Gout Flares
  • Dr. Elfishawi, et al reply
  • Drs. Dai and Felson reply
Show more Correspondence

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire